Solid Biosciences (SLDB) News Today $5.78 -0.22 (-3.67%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$6.11 +0.33 (+5.71%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Cantor Fitzgerald Brokers Boost Earnings Estimates for SLDBSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for Solid Biosciences in a research report issued on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will posFebruary 22 at 2:42 AM | marketbeat.comResearch Analysts Issue Forecasts for SLDB FY2025 EarningsSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a research report issued on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company willFebruary 21 at 8:48 AM | marketbeat.comWedbush Increases Earnings Estimates for Solid BiosciencesSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Wedbush lifted their Q1 2025 earnings per share estimates for Solid Biosciences in a note issued to investors on Wednesday, February 19th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.60) for theFebruary 21 at 7:51 AM | marketbeat.comChardan Capital Issues Positive Forecast for Solid Biosciences (NASDAQ:SLDB) Stock PriceFebruary 21 at 3:37 AM | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Given New $16.00 Price Target at Chardan CapitalChardan Capital increased their target price on shares of Solid Biosciences from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Wednesday.February 20 at 8:05 AM | marketbeat.comTruist Financial Sticks to Its Buy Rating for Solid Biosciences (SLDB)February 19 at 3:30 PM | markets.businessinsider.comSolid Biosciences Soars 32% on Trial Data: 189% Upside from Here?Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?February 19 at 8:48 AM | marketbeat.comJMP Securities Keeps Their Buy Rating on Solid Biosciences (SLDB)February 19 at 5:30 AM | markets.businessinsider.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from AnalystsShares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have earned an average rating of "Buy" from the thirteen research firms that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating and four have issued a strong buyFebruary 19 at 1:28 AM | marketbeat.comSolid Biosciences stock soars on promising Duchenne therapy dataFebruary 19 at 12:30 AM | uk.investing.comSolid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy DataFebruary 19 at 12:30 AM | benzinga.comSolid Biosciences reports initial clinical data from INSPIRE DUCHENNE trialFebruary 19 at 12:30 AM | markets.businessinsider.comSolid Bio surges after trial data for lead asset in DuchenneFebruary 19 at 12:30 AM | msn.comSolid Biosciences price target raised to $16 from $15 at ChardanFebruary 19 at 12:30 AM | markets.businessinsider.comSolid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?February 19 at 12:30 AM | msn.comSolid Biosciences Announces Pricing of Underwritten OfferingFebruary 18, 2025 | globenewswire.comSolid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003February 18, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Average Recommendation of "Buy" from BrokeragesSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has been assigned an average rating of "Buy" from the thirteen research firms that are presently covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a buy recommendation and four have issued a strong buFebruary 16, 2025 | marketbeat.comComparing Coeptis Therapeutics (NASDAQ:COEP) and Solid Biosciences (NASDAQ:SLDB)February 13, 2025 | americanbankingnews.comJMP Securities maintains Solid Biosciences stock with $15 targetFebruary 5, 2025 | msn.comSolid Biosciences director Ilan Ganot sells $447 in stockJanuary 30, 2025 | msn.comSolid Biosciences stock hits 52-week low at $3.02January 24, 2025 | msn.comSolid Biosciences receives FDA Fast Track Designation for SGT-212January 22, 2025 | markets.businessinsider.comCantor Fitzgerald Estimates SLDB FY2025 EarningsSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.45) per shaJanuary 22, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of "Buy" from AnalystsSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has earned a consensus rating of "Buy" from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and four have assigned a strong buy recommendation toJanuary 22, 2025 | marketbeat.comSolid Biosciences: Differentiating Factors Of SGT-212 To Set Itself ApartJanuary 21, 2025 | seekingalpha.comSolid Biosciences' Ataxia Treatment Receives FDA Fast-Track DesignationJanuary 21, 2025 | marketwatch.comSolid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s AtaxiaJanuary 21, 2025 | markets.businessinsider.comSolid Biosciences Reports Fast Track Designation For SGT-212 - Quick FactsJanuary 21, 2025 | markets.businessinsider.comSolid Biosciences gets FDA Fast Track for FA gene therapyJanuary 21, 2025 | msn.comSolid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's AtaxiaJanuary 21, 2025 | globenewswire.comSolid Biosciences: Promising Advancements and Strategic Initiatives Drive Buy RatingJanuary 17, 2025 | markets.businessinsider.comSolid Biosciences: Strategic Advancements and Promising Pipeline Justify Buy RatingJanuary 17, 2025 | markets.businessinsider.comSolid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic MedicinesJanuary 15, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) CFO Sells $15,843.97 in StockJanuary 14, 2025 | insidertrades.comKevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) StockSolid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 4,073 shares of the firm's stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $3.89, for a total value of $15,843.97. Following the completion of the transaction, the chief financial officer now owns 24,789 shares in the company, valued at approximately $96,429.21. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 13, 2025 | marketbeat.comPromising Developments and Strategic Advancements Support Buy Rating for Solid BiosciencesJanuary 13, 2025 | markets.businessinsider.comQ1 EPS Forecast for Solid Biosciences Reduced by AnalystSolid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a report issued on Thursday, January 9th. Leerink Partnrs analyst J. Schwartz now expects that the company will earJanuary 13, 2025 | marketbeat.comSolid Biosciences’ Innovative Gene Therapy SGT-212 Gains Buy Rating Amid Promising Preclinical Results and FDA ApprovalJanuary 11, 2025 | markets.businessinsider.comSolid Biosciences (SLDB) Receives a Buy from Piper SandlerJanuary 11, 2025 | markets.businessinsider.comSolid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Friday.January 10, 2025 | marketbeat.comSolid Biosciences: Promising Advancements in Gene Therapy and Strategic Positioning Justify Buy RatingJanuary 9, 2025 | markets.businessinsider.comSolid Biosciences: Promising Gene Therapy Advancements and Strategic Positioning Drive Buy RatingJanuary 8, 2025 | markets.businessinsider.comSolid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comSolid Bio draws buy from Truist on valuation and catalystsJanuary 8, 2025 | msn.comSolid Biosciences Outpaces Competitors In Duchenne Gene Therapy DevelopmentJanuary 8, 2025 | benzinga.comTruist Securities Initiates Coverage of Solid Biosciences (SLDB) with Buy RecommendationJanuary 8, 2025 | msn.comSolid Biosciences (NASDAQ:SLDB) Coverage Initiated by Analysts at Truist FinancialTruist Financial initiated coverage on shares of Solid Biosciences in a research report on Wednesday. They issued a "buy" rating and a $16.00 price target on the stock.January 8, 2025 | marketbeat.comSolid Biosciences Gains FDA Clearance for New Drug ApplicationJanuary 8, 2025 | marketwatch.comSolid Biosciences's IND For Gene Therapy To Treat Friedreich's Ataxia Gets FDA ClearanceJanuary 8, 2025 | markets.businessinsider.com Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address SLDB Media Mentions By Week SLDB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SLDB News Sentiment▼0.870.60▲Average Medical News Sentiment SLDB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SLDB Articles This Week▼223▲SLDB Articles Average Week Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kura Oncology News Today CorMedix News Today Arbutus Biopharma News Today Pharming Group News Today Immatics News Today ORIC Pharmaceuticals News Today Rapport Therapeutics News Today Septerna News Today Precigen News Today Stoke Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SLDB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
